Monopar Therapeutics Debt-to-Equity Ratio Growth & History (MNPR)

Monopar Therapeutics's debt-to-equity ratio was 0.00 for fiscal 2025.

View full Monopar Therapeutics company overview

Monopar Therapeutics annual debt-to-equity ratio history

Monopar Therapeutics annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.000.00
20242024-12-310.00−0.00
20232023-12-310.00−0.00−73.36%
20222022-12-310.010.01
20212021-12-310.00

Monopar Therapeutics debt-to-equity ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, Monopar Therapeutics's debt-to-equity ratio increased from 0.00 to 0.00, a change of 0.00. The latest reported quarter, Q2 2026, shows 0.00.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Monopar Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about MNPR yet. Start the conversation.

Write the first post